A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

Proceeds to support registration-enabling trials, DOMMINO-1 and DOMMINO-2, and continued development of the first-in-class p300/CBP inhibitor Financing led by Venrock Healthcare Capital Partners, with ...

In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

Markedly increased risk seen for hematologic second primary malignancies, reduced risks for CLL, head and neck cancer, bladder cancer, breast cancer.

We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

Eligible Australians with multiple myeloma will now have access to a new free therapy, Carvykti, in public hospitals across Australia thanks to the ...